AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY): The Diabetes Pipeline With a Clog

Page 1 of 2

Eli Lilly & Co. (NYSE:LLY)Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE:JNJ), Eli Lilly & Co. (NYSE:LLY), and the partnership of Bristol Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (ADR) (NYSE:AZN). But the path to market proved tricky.

Johnson and Johnson (NYSE:JNJ)’s Invokana earlier this year became the first SGLT2 approved in the United States. Bristol Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (ADR) (NYSE:AZN)’s Forxiga was the first out in Europe but remains stuck in the Food and Drug Administration’s pipes.  Could Eli Lilly & Co. (NYSE:LLY)’s empagliflozin follow Invokana to the U.S. market — or will it become stuck behind Forxiga?

And how much does an SGLT2 win even matter to these companies?

Bumpy road for SGLT2s

SGLT2s were hyped because they’re insulin-independent, which means they can fit into a combo therapy with insulin without risking counteraction. The class also has the potential to become a blockbuster market, with sales of Invokana predicted to reach $1 billion by 2018.

But the FDA has become notoriously skittish when it comes to the safety of diabetes drugs.

Bristol Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (ADR) (NYSE:AZN)’s SGLT2 received European approval under the name Forxiga, and brought in $3 million in the first quarter. But an FDA approval hangs just out of reach due to concerns of cancer risks. An advisory committee voted 9-6 that the safety and efficacy data wasn’t sufficient to support an approval. Then the FDA issued a complete response letter requesting more data.

Johnson and Johnson (NYSE:JNJ)’s Invokana didn’t show any of Forxiga’s cancer risks. But the drug did need to undergo long-term cardiovascular trials, which should wrap up in 2015. And coming first into the U.S. could provide Johnson with the market advantage.

Which path will Eli Lilly & Co. (NYSE:LLY)’s pipeline contender follow?

Lilly’s contender

Eli Lilly & Co. (NYSE:LLY) provided a glimpse at empagliflozin’s late-stage data during the American Diabetes Association meeting last month. Empagliflozin went up against placebo and showed improvements in reducing blood sugar, blood pressure, and weight. But the drug also showed an increased chance of genital infection due to the glucose that leaves the body through urine.

There’s a good chance the FDA won’t issue a denial or complete response letter based solely on the risk of genital infection. That’s not quite in the same ballpark as Forxiga’s cancer concerns. A cardiovascular safety requirement is more likely, but could be met with data from the late-stage trials.

It’s a fool’s errand these days to guess which way the FDA will rule on a diabetes drug’s safety. But we should have an idea of the agency’s direction soon; Lilly filed its new drug application in March.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!